Nasal Congestion
Conditions
Brief summary
This study will assess the food-effect bioavailability of an extended release formulation of phenylephrine HCl and its bioequivalence to the marketed immediate release phenylephrine HCl product.
Interventions
DRUGPhenylephrine HCl Extended Release
One phenylephrine HCl 30 mg extended release tablet orally
DRUGPhenylephrine HCl Immediate Release
One phenylephrine HCl 10 mg immediate release tablet every 4 hours for three doses
Sponsors
Bayer
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* In good health * Female participants must not be pregnant * Agrees to use two acceptable methods of birth control throughout the study * Agrees not to take monoamine oxidase inhibitor (MAOI) for 2 weeks prior to, during, and 2 weeks after the end of the study
Exclusion criteria
* Any significant medical condition which is a contraindication to the use of phenylephrine HCl, might interfere with the study, or requires treatment expected to affect blood pressure * Any infectious disease within 4 weeks prior to initial treatment administration * History of malignancy, except basal cell carcinoma * Cannot comply with requirement to abstain from the use of any drugs (except acetaminophen or herbal/vitamin supplements) within 14 days prior to study and alcohol or xanthine-containing substances (coffee, chocolate) within 72 hours prior to study * Received an investigational drug within thirty days prior to study drug dosing * Known or apparent current or former drug addicts or alcoholics * Positive for Human Immunodeficiency Virus (HIV) antibody, hepatitis B surface antigen, or hepatitis C antibody * Cannot accept a high-fat, high-calorie breakfast * Known allergy or intolerance to phenylephrine HCl * Have used phenylephrine-containing product within 2 weeks prior to study start * Have smoked tobacco, used tobacco products, or used a nicotine-containing smoking cessation aid within the past 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum plasma concentration (Cmax) of phenylephrine | 0 hours to time of maximum observed plasma concentration of phenylephrine (blood samples will be collected up to 24 hours after first administration of study treatment) |
| Time to Cmax (Tmax) of phenylephrine | 0 hours to time of maximum observed plasma concentration of phenylephrine (blood samples will be collected up to 24 hours after first administration of study treatment) |
| Area under the concentration versus time curve from time 0 to the last measurable concentration (AUC[0-t]) | 0 hours to time of last measurable plasma concentration of phenylephrine (blood samples will be collected up to 24 hours after first administration of study treatment) |
| Area under the concentration versus time curve from time 0 to infinity (AUC[0-∞]) | 0 hours to time of last measurable plasma concentration of phenylephrine (blood samples will be collected up to 24 hours after first administration of study treatment) |
| Terminal rate constant (λz) | 0 hours to time of last measurable plasma concentration of phenylephrine (blood samples will be collected up to 24 hours after first administration of study treatment) |
| Terminal elimination half-life (t1/2) | 0 hours to t1/2 of phenylephrine (blood samples will be collected up to 24 hours after first administration of study treatment) |
Outcome results
None listed